How to design and launch a successful Clinical Trial Manufacturing.

Introduction: The DNA of a Biotech BoomThe global plasmid DNA manufacturing market is entering a transformative era, driven ...

The COVID-19 pandemic demonstrated that the mass production of vaccines is crucial for our healthcare system. In order to ...

Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

Novartis invested €40 million (US$43 million) into the facility, which is the company’s first specialized viral vector manufacturing facility in ... and efficiency at all stages of the production ...

Comprehensive Analysis of Market Dynamics, Emerging Technologies, and ESG Trends Shaping the Future of Bioprocess Optimization and Digital Bio-manuf ...

Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based on myvac® platform Strasbourg, ...

Q4 2024 Earnings Conference Call April 9, 2025 8:00 AM ET. Company Participants. Frank Mathias - Chief Executive Officer Sebastien Ribault - Chi ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

Carefully managing the operating conditions of logic cells and embedded memories directly impacts power consumption.

The challenge today is not predicting what comes next; rather, it is keeping up with what is already happening. AI has moved ...

The discussion covered emerging biologics, AI applications, and a strategy for supporting biomanufacturing in the current political climate.